Zenas BioPharma, Inc. (ZBIO) income statement
ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$26.42−1.33 (-4.79%)
Close on Nov 18, 2026Market cap $1.72BP/E –Yield –
Zenas BioPharma, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -5264.0%
- Net margin
- -5418.1%
- Return on equity, FY2025
- -136.2%
Financial strength
- Current ratio
- 9.42
- Debt to equity
- 1.05
- Debt to assets
- 33.1%
- Cash to current liabilities
- 277.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.11
- Dividend yield
- –
See a number that looks wrong?